Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Multiple myeloma


Other Names for this Disease
  • Kahler disease
  • Myeloma - multiple
  • Myelomatosis
  • Plasma cell dyscrasia
  • Plasma cell myeloma
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment


Newline Maker

How might multiple myeloma be treated?

The goal of treatment is to relieve symptoms, avoid complications, and prolong life. Those with mild disease or where the diagnosis is not certain are usually carefully watched without treatment. Some people have a slow-developing form that takes years to cause symptoms.  Medications for the treatment of multiple myeloma include:[1]
  • Dexamethasone, melphalan, cyclophosphamide, doxil, thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade) can be used alone or combined together.
  • Bisphosphonates (pamidronate) to reduce bone pain and prevent fractures.

Radiation therapy may be done to relieve bone pain or treat a bone tumor.[1]

Two types of bone marrow transplantation may be tried:[1]
  • Autologous bone marrow or stem cell transplantation makes use of one’s own stem cells. In younger patients, it has been shown to increase survival.
  • Allogeneic transplant makes use of someone else’s stem cells. This treatment carries serious risks but offers the chance of a cure.
Last updated: 7/6/2011

References
  1. Multiple Myeloma. MedlinePlus. February 2011; http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm. Accessed 7/6/2011.


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Multiple myeloma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Melphalan
Trade Name
(Manufacturer Name)
Alkeran® (injection)
(Glaxo Wellcome Inc.)
Indication
The FDA has approved this product to be used in this manner.
For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Doxorubicin HCL liposome injection
Trade Name
(Manufacturer Name)
Doxil® (injection)
(Centocor Ortho Biotech Inc.)
Indication
The FDA has approved this product to be used in this manner.
For use in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have at least one prior therapy.
More Information about this product Drug Information Portal

Generic Name Carfilzomib
Trade Name
(Manufacturer Name)
Kyprolis
(Onyx Therapeutics, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
More Information about this product Drug Information Portal

Generic Name Pomalidomide
Trade Name
(Manufacturer Name)
Pomalyst
(Celgene Corporation)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Lenalidomide
Trade Name
(Manufacturer Name)
Revlimid®
(Celgene Corporation)
Indication
The FDA has approved this product to be used in this manner.
For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy.
More Information about this product Drug Information Portal

Generic Name Thalidomide
Trade Name
(Manufacturer Name)
Thalomid®
(Celgene Corporation)
Indication
The FDA has approved this product to be used in this manner.
Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Bortezomib
Trade Name
(Manufacturer Name)
Velcade®
(Millennium Pharmaceuticals, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of multiple myeloma patients who have received at least one prior therapy
More Information about this product Drug Information Portal
Medline Plus Health Information